New antibody drugs for advanced HER2-positive cancers
Treatments studied
Part of Cancer clinical trials.
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Advanced or metastatic cancer confirmed by biopsy or cell sample (colorectal, bladder, breast, biliary, stomach, or similar solid tumors)
- Good overall health and ability to care for yourself (ECOG score 0–1, meaning you can do light activities)
- Expected to live at least 3 months
- No serious side effects remaining from prior cancer treatments (except hair loss, tiredness, or mild nerve damage)
- Normal or near-normal organ and bone marrow function, and not pregnant or nursing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
This trial tests two new immunotherapy drugs (SHR-A1811 and SHR-A1701) given before surgery to treat advanced stomach or gastroesophageal junction cancer. The goal is to shrink the tumor and help your immune system fight the cancer before surgical removal.
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This study tests a new treatment combining two drugs (SSGJ-612 and an antibody-drug) for people with a certain type of advanced breast cancer (hormone receptor-positive and HER2-low or ultra-low). The goal is to see if this combination can help when endocrine therapy has stopped working.
Hear when a new Locally Advanced (Unresectable) or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.